Global Analysis for Ebolavirus Infections (Ebola Hemorrhagic Fever) Clinical Trials & Evaluation on Approved Therapies Reviewed in H2, 2017

Posted on 2017-09-27 by Mark Hub in Internet & Online // 0 Comments

MARKET RESERACH HUB

Albany, US, 2017-Sep-27 — /EPR Network/ — Ebola Virus Disease (EVD) is a life-threatening and contagious disease which is contracted by human beings as well as primates. The disease has a case fatality rate up to 90%. The ongoing outbreak of Ebola virus disease in West Africa highlighted the lack of a licensed drug or vaccine to combat the disease and has renewed the urgency to develop a pipeline of Ebola vaccine. The researchers have been trying to better understand this virus and target its ecological reservoirs in order to get a deeper understanding of the cause and nature of the outbreaks of this disease. Recently, a new clinical trial study titled “Ebolavirus Infections (Ebola Hemorrhagic Fever) Global Clinical Trials Market Reports Review, H2, 2017” has been broadcasted to the wide archive of Market Research Hub (MRH). This study retorts to questions about clinical trials and assessments of possible vaccines, therapies and diagnostics for Ebola virus disease.

Request free Sample Report: https://www.marketresearchhub.com/enquiry.php?type=S&repid=1326304

Ebola virus disease (EVD), a severe viral hemorrhagic fever syndrome caused by Ebola virus (EBOV) is transmitted by direct contact with the body fluids of infected person and objects contaminated with virus or infected animals. Symptoms begin with fever and muscle aches and progress to breathing problems, severe bleeding, kidney problems, and shock. The infection may be mild, but it can also lead to death. The vaccine used in this study is made from small parts of Ebola genetic material.

Initially, this report provides top-line data relating to the clinical trials on Ebolavirus Infections (Ebola Hemorrhagic Fever). In addition, it offers an overview of trial numbers and their average enrollment in top countries conducted across the globe. The subsequent section analyzes the top countries contributing to clinical trials, mainly in Asia-Pacific, North America, Europe, Middle East & Africa. The report offers coverage of disease clinical trials by region, country (both in G7 & E7), phase, trial status, endpoints status and sponsor type. It has been analyzed that there are 15 different vaccines are in preclinical development and 8 vaccines are now in different stages of clinical evaluation.

Further in the report, based on a number of ongoing trials, report also provides prominent drugs for in-progress trials. It has been stated that the pharmaceutical companies have a significant opportunity in the field of ebola virus infections in terms of developing drugs, vaccines and introducing measures to control and prevent the spread of the disease.

Browse Full Report With TOC: https://www.marketresearchhub.com/report/ebolavirus-infections-ebola-hemorrhagic-fever-global-clinical-trials-review-h2-2017-report.html

Moreover, the report reviews top companies involved and enlists all their trials. Key companies are Johnson & Johnson, GlaxoSmithKline Plc., Bavarian Nordic A/S, Tianjin CanSino Biotechnology Inc., Merck & Co Inc., ICON Plc., NewLink Genetics Corp., Arbutus Biopharma Corp., Chimerix Inc., and Gilead Sciences Inc.

Enquire About this Report: https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1326304

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of pharmaceutical market reports and analysis. MRH’s expansive collection of reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick